Mode
Text Size
Log in / Sign up
Phase 4 N=26 Randomized Single-blind Treatment

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

Acne Vulgaris

Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Jan 2012
Primary outcome: Primary: Expert Grader Assessment - Erythema — 0.0; 0.0; 0.4; 2.0 Scores on a Scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Dapsone plus Tretinoin Gel (Drug); Tretinoin Gel (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Bausch Health Americas, Inc.
Primary completion
Dec 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Expert Grader Assessment - Erythema
0.0; 0.0; 0.4; 2.0; 0.4; 2.0
PRIMARY
Expert Grader Assessment - Dryness
0.0; 0.0; 0.6; 1.8; 1.7; 2.5
SECONDARY
Subject Assessment - Burning/Stinging
1.0; 0.0; 2.6; 1.6; 1.8; 2.6
SECONDARY
Subject Assessment - Itching
0.0; 0.0; 1.6; 2.8; 0.5; 1.9
SECONDARY
Subject Assessment - Tightness
0.0; 0.0; 1.5; 1.8; 1.5; 2.9
SECONDARY
Facial Tolerance
1.0; 0.0; 6.7; 10.0; 5.9; 11.9

Summary

This study is to see if there's any difference in the amount of facial irritation when two acne products are used together on one side of the face, compared to one acne treatment product used alone on the other side of the face. All people participating in this trial will be required to return to the same study center every weekday for two weeks for the investigator to check for irritation on the face and to have the products applied - on weekends they will have to put them on at home. If one side of the face is more irritated than the other side, a picture will be taken as well.

Eligibility Criteria

Inclusion Criteria

  • Fitzpatrick Skin Type I, II or III with healthy skin as judged by the investigator
  • Bilateral skin is clear of any confounding irritation, rashes, acne, rosacea, etc., prior to study start
  • Subjects are willing to avoid applying emollients or cosmetics to the face 24 hours before they start, and during the study
  • If subject is of childbearing potential, subject has been using a protocol-approved method of birth control for a certain amount of time, and is willing to continue using it throughout the study

Exclusion Criteria

  • Subjects who are pregnant or nursing, or intend to be during the study
  • Subjects with any condition or medical history, or using any drug or medication, that might negatively affect the subject's safety or the validity of study results, either as listed in the protocol or in the opinion of the investigator
  • Subjects who have facial hair that may obstruct or hinder the evaluation of any reactions
  • Subjects who use any known photosensitizing agents
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01313728). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search